Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Tiziana Life Sciences (NASDAQ: TLSA), a clinical-stage biotechnology company focused on developing immunotherapies, will soon announce the 6-month results for patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS) receiving its novel intranasal treatment, foralumab.
Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in microglia activity,
Program advances to lead compound evaluation in preclinical in vivo models
Preliminary data for in vivo studies are expected in second half of 2023
SAN DIEGO, June 20, 2023 /PRNewswire/ Regulus. | June 20, 2023